Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for carfilzomib or regorafenib; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; if approved, we or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib or regorafenib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, regorafenib or carfilzomib; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables)ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2011201020112010Revenue: Revenue from collaboration agreement

$  75,041$63,696$ 
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... HeartSine Technologies received the Outstanding Achievement in Business ... 25th, in Belfast, Northern Ireland. The award honors an ... and surrounding communities. The Aisling Award was ... 1997 to honor champions and ambassadors from every field ...
... (Nasdaq: ELGX ), developer of minimally invasive ... Managing Director at Essex Woodlands Health Ventures, has joined ... majority shareholder of Nellix Inc, which was acquired by ... 2010. In conjunction with the acquisition, Essex Woodlands made ...
Cached Medicine Technology:HeartSine Technologies Wins 2010 Aisling Award for Outstanding Achievement in Business 2Endologix Appoints Guido Neels to Its Board of Directors 2Endologix Appoints Guido Neels to Its Board of Directors 3
(Date:7/11/2014)... The American Association of Poison Control ... are commending Senator Bill Nelson (D-FL) for his introduction ... on July 10, 2014. Along with fellow Senate co-sponsors, ... (CPSC) to enact rules requiring safer, child-resistant packaging for ... Senate co-sponsors of the bill include: Sen. Richard Blumenthal ...
(Date:7/11/2014)... Ticket Down reports that tickets to the Argentina ... Cup Match between Brazil and Netherlands are in ... Saturday, July 12th at Estadio Nacional de Brasilia Mane Garrincha ... on Sunday, July 13th at Estadio Jornalista Mario Filho - ... 2014 World Cup are guaranteed to be authentic and are ...
(Date:7/11/2014)... Butler Mobility has recently updated the paint color choices for ... the two standard colors were beige and brown. Butler ... standard colors at no additional charge! These colors will ... the beauty of the stairway. Homeowners will find a ... décor. , The new selection of standard colors is: , ...
(Date:7/11/2014)... the lowest incomes may have a higher risk for a ... suggests. People with PAD have narrowing of the arteries ... The condition causes leg pain and is often an indicator ... PAD have a higher risk for heart disease and stroke. ... who took part in the U.S. National Health and Nutrition ...
(Date:7/11/2014)... Volunteers from Scientology Churches ... week with drug education lectures, forums and conferences, information ... cities around the world. , Drug abuse is an ... Drug Abuse, abuse of alcohol and illicit drugs costs ... work, decreased productivity and healthcare. , In the ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... ... Group in Boston, at The Liberty Hotel today, which for the first time includes ... to connect and exchange data with other applications. , ... Boston, Massachusetts (Vocus) October 20, 2009 -- ...
... RICHMOND, Calif., Oct. 20 ... the presentation of top-line, statistically significant Phase 2 clinical ... as a treatment for diabetic neuropathy (DN) at the ... Top-line data from Sangamo,s SB-509-601 Phase 2 clinical trial ...
... 20 In testimony to a U.S. House of ... ways to better meet the needs of every community ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , Trevor Riggen, Red ... to how the Red Cross is meeting the needs ...
... advanced liver disease who drink three or more cups of ... disease progression than non-coffee drinkers according to a new study ... Institute (NCI). The study found that patients with hepatitis ... standard disease treatment benefited from increased coffee intake. An ...
... Sponsor Event to Earn the World Record for the Most Massages ... On Sunday, October 25, Massage Envy will sponsor an event ... massaged simultaneously in one location. The goal is to have ... 34th annual Marine Corps Marathon. There will be a sea ...
... (HCC) or primary liver cancer forms in the epithelial tissue ... hepatitis B virus (HBV) or hepatitis C virus (HCV). ... 15,000 men and 6,000 women are diagnosed with HCC each ... highest regions being Western Pacific and Africa according to a ...
Cached Medicine News:Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 2Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 3Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 4Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 2Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 3Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 4Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 5Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 6Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 7Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 8Health News:Red Cross Strives to Help Disaster's Vulnerable Population 2Health News:Red Cross Strives to Help Disaster's Vulnerable Population 3Health News:Drinking coffee slows progression of liver disease in chronic hepatitis C sufferers 2Health News:Record-Breaking Relaxation at Marine Corps Marathon 2Health News:Scientists identify specific markers that trigger aggressiveness of liver cancer 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: